Last edition
News about "Gilead PepStar Therapeutics Deal"
Gilead to Acquire IL-23R Inhibitor HCXT-2001 for IBD
Gilead plans to acquire HCXT-2001, an investigational oral IL-23 receptor inhibitor, to strengthen its inflammation pipeline and address unmet needs in IBD.
Gilead PepStar Therapeutics Deal | 24/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members